C
Carlo Andrea Bravi
Researcher at Vita-Salute San Raffaele University
Publications - 153
Citations - 1264
Carlo Andrea Bravi is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 48 publications receiving 585 citations. Previous affiliations of Carlo Andrea Bravi include Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
Arianna Calcinotto,Clarissa Spataro,Elena Zagato,Diletta Di Mitri,Veronica Gil,Mateus Crespo,Gaston De Bernardis,Marco Losa,Michela Mirenda,Emiliano Pasquini,Andrea Rinaldi,Semini Sumanasuriya,Maryou B. Lambros,Antje Neeb,Roberta Lucianò,Carlo Andrea Bravi,Daniel Nava-Rodrigues,David Dolling,Tommaso Prayer-Galetti,Ana Ferreira,Alberto Briganti,Antonio Esposito,Simon T. Barry,Wei Yuan,Adam Sharp,Johann S. de Bono,Andrea Alimonti +26 more
TL;DR: Results reveal that MDSCs promote CRPC by acting in a non-cell autonomous manner and Treatments that block IL-23 can oppose MDSC-mediated resistance to castration in prostate cancer and synergize with standard therapies.
Journal ArticleDOI
Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
Giorgio Gandaglia,Nicola Fossati,Emanuele Zaffuto,Marco Bandini,Paolo Dell'Oglio,Carlo Andrea Bravi,Giuseppe Fallara,Francesco Pellegrino,Luigi Nocera,Pierre I. Karakiewicz,Zhe Tian,Massimo Freschi,Rodolfo Montironi,Francesco Montorsi,Alberto Briganti +14 more
TL;DR: A lymph node dissection exclusively in men with a risk of LNI >7% according to this model would significantly reduce the number of unnecessary pelvic nodal dissections with arisk of missing only 1.5% of patients with LNI.
Journal ArticleDOI
Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis
Nicola Fossati,Nazareno Suardi,Giorgio Gandaglia,Carlo Andrea Bravi,Matteo Soligo,R. Jeffrey Karnes,Shahrokh F. Shariat,A. Battaglia,Wouter Everaerts,Steven Joniau,Hendrik Van Poppel,Nieroshan Rajarubendra,Inderbir S. Gill,Alessandro Larcher,Alexander Mottrie,Maximilian Schmautz,Axel Heidenreich,Almut Kalz,Daniar Osmonov,Klaus P. Juenemann,Annika Herlemann,Christian Gratzke,Christian Gratzke,Christian Stief,Francesco Montorsi,Alberto Briganti +25 more
TL;DR: The risk of early clinical recurrence after salvage lymph node dissection (SLND) was estimated to be approximately 25% in this paper, with a Kaplan-Meier probability of eCR equal to 25%.
Journal ArticleDOI
The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study.
Carlo Andrea Bravi,Carlo Andrea Bravi,Amy Tin,Emily Vertosick,Elio Mazzone,Alberto Martini,Paolo Dell'Oglio,Armando Stabile,Giorgio Gandaglia,Nicola Fossati,Nazareno Suardi,Andrea Gallina,Alberto Briganti,Francesco Montorsi,Andrew J. Vickers +14 more
TL;DR: The impact of experience on cancer control after robotic prostatectomy differed from that in the prior literature on open and laparoscopic radical prostateCTomy, and should be investigated in larger multi-institutional studies.
Journal ArticleDOI
Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought
Carlo Andrea Bravi,Nicola Fossati,Giorgio Gandaglia,Nazareno Suardi,Elio Mazzone,Daniele Robesti,Daniar Osmonov,Klaus P. Juenemann,Luca Boeri,Luca Boeri,R. Jeffrey Karnes,Alexander Kretschmer,Alexander Buchner,Christian G. Stief,Andreas Hiester,Alessandro Nini,Alessandro Nini,Peter Albers,Gaëtan Devos,Steven Joniau,Hendrik Van Poppel,Shahrokh F. Shariat,Axel Heidenreich,David Pfister,Derya Tilki,Markus Graefen,Inderbir S. Gill,Alexander Mottrie,Pierre I. Karakiewicz,Francesco Montorsi,Alberto Briganti +30 more
TL;DR: In this paper, the authors investigated long-term oncological outcomes after sLND in a large multi-institutional series, including 189 patients who experienced prostate-specific antigen (PSA) rise and nodal-only recurrence after radical prostatectomy.